EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review

Pavan Tenneti iD, Umar Zahid, Ahmad Iftikhar, Seongseok Yun iD, Atif Sohail, Zabih Warraich, Faiz Anwer iD

Sarcoma · 03.06.2018 · 2018 · 1-12

DOI: 10.1155/2018/2640674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Sarcoma, erschienen am 03.06.2018. Verfasst von Pavan Tenneti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Arizona, Tucson, AZ 85721, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapsed Ewing’s sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES.

Methods

Literature search involved Medline, Embase, and Cochrane database. We included studies with RES patients treated with HDCT/ASCT.

Results

Twenty-four studies with total of 345 reported RES patients that got HDCT were included in final analysis. Seventeen studies had patients with multiple malignancies including RES, while seven had only RES patients. At 2 and 3–5 years, event-free survival (EFS) in studies with only RES patients ranged 42–47% and 20–61% and overall survival (OS) ranged 50–66% and 33–77%, respectively. In studies with combined patients that reported outcomes of RES separately, the EFS at 1–3 and 4 years was 36–66% and 17–50%, respectively. The OS at 1-2 and 3-4 years was 40–60% and 50–70%.

Conclusions

Most studies using HDCT/ASCT as consolidation regimen showed improved survival benefits compared to CC. Randomized controlled studies are needed to determine true clinical benefits of HDCT followed by ASCT in patients with RES.

Autor:innen und Institutionen

  • Department of Medicine, University of Arizona, Tucson, AZ 85721, USA.
  • Department of Biostatics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ 85721, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Arizona, Tucson, AZ 85721, USA.
  • Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

ORCID-Profile: Pavan Tenneti, Seongseok Yun, Faiz Anwer

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Tenneti, P., Zahid, U., Iftikhar, A., Yun, S., Sohail, A., Warraich, Z., & Anwer, F. (2018). Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review. Sarcoma, 2018, 1-12. https://doi.org/10.1155/2018/2640674

Vancouver

Tenneti P, Zahid U, Iftikhar A, Yun S, Sohail A, Warraich Z, et al. Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review. Sarcoma. 2018;2018:1-12. doi:10.1155/2018/2640674

BibTeX
@article{Tenneti2018,
  author = {Tenneti, Pavan and Zahid, Umar and Iftikhar, Ahmad and Yun, Seongseok and Sohail, Atif and Warraich, Zabih and Anwer, Faiz},
  title = {Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review},
  journal = {Sarcoma},
  year = {2018},
  volume = {2018},
  pages = {1--12},
  doi = {10.1155/2018/2640674}
}
Kostenlos starten →